Clinical trials: SGLT2 Inhibitor Use
Diabetes Mellitus, Type 2
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy…
- Trial name
- NCT02284269
- Testing
- SGLT2 Inhibitors
- Volunteers
- 18,000 people
- Sponsor
- Pharmaceuticals and Medical Devices Agency, Japan
Renal Insufficiency, Chronic, Cardiac Catheterization
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as…
- Conditions
- Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
- Trial name
- NCT05225077
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Prediabetes
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes.
- Trial name
- PREVNT (NCT06828731)
- Testing
- Empagliflozin 10mg daily, Lifestyle education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Charles George VA Medical Center
Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- SGLT2i-AMI (NCT07198191)
- Testing
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), DPP4 inhibitors
- Where
- South Korea
- Volunteers
- 200,000 people
- Sponsor
- Yonsei University
Hypertrophic Cardiomyopathy, Heart Failure
Empagliflozin in Hypertrophic Cardiomyopathy
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study.
- Trial name
- EMPA-REPAIR (NCT05182658)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 250 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Sepsis, Septic Shock
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury
- Trial name
- NCT06902493
- Testing
- No intervention
- Where
- Saudi Arabia
- Volunteers
- 664 people
- Sponsor
- University of Jazan
Diabetic Foot Ulcer
SGLT-i Use in Diabetic Foot Ulcer Disease
Background: People with diabetes and either current or previous diabetic foot ulcer disease (DFUD) are at very high risk for adverse cardiovascular events including heart attacks and strokes.
- Trial name
- NCT06000722
- Testing
- eDelphi method
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Pneumonia, Type 2 Diabetes Mellitus (T2DM)
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes…
- Trial name
- NCT07708610
- Where
- Taiwan
- Volunteers
- 71,775 people
- Sponsor
- Chung Shan Medical University
Type 2 Diabetes Mellitus, Acute Kidney Injury
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
This pilot study will evaluate the feasibility of using a clinical decision support(CDS) message to support consideration of SGLT2 inhibitor prescribing in patients with type 2 diabetes who recently had acute kidney injury.
- Conditions
- Type 2 Diabetes Mellitus, Acute Kidney Injury, Chronic Kidney Diseases, SGLT2 Inhibitor Use
- Trial name
- NCT07868666
- Testing
- Clinical Decision Support Message
- Volunteers
- 250 people
- Sponsor
- University of Minnesota
SGLT2 Inhibitors, First Time Use, Type2 Diabetes
First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy
All healthy Muslim adults are required to observe the Ramadan fast, which is one of Islam's five pillars. People with Type 2 Diabetes Mellitus frequently fast throughout Ramadan (T2DM).
- Conditions
- SGLT2 Inhibitors, First Time Use, Type2 Diabetes, Fasting in Ramadan
- Trial name
- NCT06370247
- Testing
- HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Diabetes Mellitus, Type 2
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
A prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period.
- Trial name
- NCT05944432
- Testing
- FreeStyle Libre 3 Continuous Glucose Monitoring System., Self monitoring of blood glucose
- Where
- 25 sites in United Kingdom
- Volunteers
- 469 people
- Sponsor
- Abbott Diabetes Care
Diabete Mellitus
Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients
Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months.
- Trial name
- NCT07367555
- Testing
- Oral 100 gram Empagliflozin tablet along with diet plan and exercise, Diet plan and exercise
- Where
- Pakistan
- Volunteers
- 360 people
- Sponsor
- Ariba Shafiq
Acute Ischemic Stroke From Large Vessel Occlusion
SGLT2 Inhibitor Utilization Re-perfusion Therapy
Background: Reperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke.
- Trial name
- SUPER (NCT06858436)
- Testing
- Canagliflozin 100mg
- Volunteers
- 150 people
- Sponsor
- Taichung Veterans General Hospital
Heart Failure
The Fontan Dapagliflozin Pilot Study
The goal of this clinical trial is to study if an investigational study drug called Dapagliflozin could prevent heart failure from getting worse in adults with Fontan circulation. The main questions it aims to answer are: 1.
- Trial name
- FonDap (NCT05741658)
- Testing
- Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Type 2 Diabetes
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets
- Trial name
- STELLALONGTERM (NCT02479399)
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 11,412 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
- Trial name
- HALLMARK (NCT05938712)
- Testing
- Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Heart Failure, Anthracycline-induced Cardiac Toxicity
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused…
- Conditions
- Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness
- Trial name
- Alpaca (NCT07245069)
- Testing
- Dapagliflozin 10 mg
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Type 2 Diabetes, Urinary Tract Infections
SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
In this observational study, 60 subjects with type 2 diabetes (T2D) and eligible, as per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2 inhibitor or a fixed dose combination of…
- Trial name
- UTI-flog (NCT04735042)
- Testing
- Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Pisa
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- REMOTE-HF (NCT07022379)
- Testing
- SGLT2 Inhibitor Use
- Where
- France
- Volunteers
- 13,660 people
- Sponsor
- Satelia
Type 2 Diabetes
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.
- Trial name
- STELLA-ELDER (NCT02297620)
- Testing
- Suglat®
- Where
- 8 sites in Japan
- Volunteers
- 8,687 people
- Sponsor
- Astellas Pharma Inc